Australian Drug Maker Has Low Profile but Powerful Backers in Washington
Tuesday, January 17, 2017 - 09:11
in Mathematics & Economics
Representatives Chris Collins and Tom Price and other power players have substantial investments in Innate Immunotherapeutics, a company with no approved drugs.